-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
To guide treatment decisions for multiple myeloma (MM), there are multiple risk stratification systems in place to distinguish between different risk levels in patients at the time of diagnosis, including ISS and R-ISS
。 R-ISS includes elevated lactate dehydrogenase (LDH) and high-risk cytogenetic abnormalities (HRCA) such as del(17p), t(4;14), and t(14;16), but the influence or weight of various baseline risk factors in estimating outcomes in MM patients may change as MM treatment patterns shift, such as other high-risk cytogenetic abnormalities that are partially not included in R-ISS (e.
In order to further test the prognostic value of the MASS staging system in newly diagnosed MM patients in China, Professor Dai Yun and Professor Jin Fengyan of the First Hospital of Jilin University led the analysis of clinical retrospective data of MM patients in 7 centers in China from November 27, 2009 to November 20, 2019, and the results of the study were published in the Blood Cancer Journal
.
References
Peiyu Yang, Fan Zhou, Yujun Dong,et al.